Therapeutic Action
Antifibrinolytic
Source page 315
Loading InternPractice…
Individual generic drug information
Extracted information for TRANEXAMIC acid only.
Antifibrinolytic
Source page 315
Abnormal uterine bleeding (especially functional uterine bleeding unrelated to pregnancy)
Source page 315
Extracted information for TRANEXAMIC acid only.
Do not administer in patients with (or with history of) venous or arterial thromboembolic disorders, severe renal impairment, history of seizures. Reduce dosage in patients with mild to moderate renal impairment (risk of accumulation). May cause: gastrointestinal disturbances, seizures with high doses, visual disturbances, allergic reactions. Avoid combination with drugs that increase the risk of thromboembolism. Concomitant use of oestrogens (e.g. ethinylestradiol/levonorgestrel) should be carefully considered on a case-by-case basis. Pregnancy: this drug is not indicated in the event of bleeding during pregnancy. Breast-feeding: no contra-indication
Source page 315
Extracted information for TRANEXAMIC acid only.
500 mg tablet
Source page 315
Adolescent and adult: 1 g 3 times daily (max. 1 g 4 times daily) until bleeding stops (max. 5 days)
Source page 315
Extracted information for TRANEXAMIC acid only.
The treatment may be administered at each bleeding episode. In situations of repeated bleeding, it may be helpful to combine tranexamic acid with a non-steroidal anti-inflammatory drug and/or a long-term treatment with a levonorgestrel intrauterine device or ethinylestradiol/levonorgestrel or oral or injectable medroxyprogesterone.
Source page 315
Below 25 °C
Source page 316
Filter the extracted dose blocks for this individual drug.
1 g 3 times daily (max. 1 g 4 times daily) until bleeding stops (max. 5 days)
Candidate age grouping · source page 315